Skip to main content
NCBI home page
Infection and Immunity logoLink to Infection and Immunity
. 1986 Jul;53(1):6–12. doi: 10.1128/iai.53.1.6-12.1986

Modulation of cellular immune responses in mice with disseminated histoplasmosis by recombinant interleukin-2.

G S Deepe Jr, C L Taylor, J E Harris, W E Bullock
PMCID: PMC260067  PMID: 3487507

Abstract

Depression of the cellular immune responses in mice with disseminated histoplasmosis is associated with deficient production of interleukin-2 (IL-2) by splenocytes. Therefore, we examined whether a highly purified preparation of IL-2, recombinant human IL-2 (rIL-2), could modify the cellular immune responses in infected mice and whether this lymphokine could alter the severity of histoplasmosis in animals. Exogenous rIL-2, at concentrations of up to 1,000 U/ml, failed to augment the proliferative responses to concanavalin A by unfractionated splenocytes or splenic T cells from mice infected for 1 week. In addition, rIL-2 did not modulate the plaque-forming cell response to sheep erythrocytes by splenocytes from these same mice. However, at week 3, rIL-2 in concentrations ranging from 10 to 1,000 U/ml considerably augmented the proliferative response to concanavalin A and plaque-forming cell response to sheep erythrocytes by splenocytes from infected mice. Kinetics studies demonstrated that rIL-2 exerted maximal immunoregulatory activity when added on day 0 or 1 to cultures of splenocytes. In vivo administration of rIL-2, 200 to 20,000 U/day, for 10 days to normal and 3-week-infected mice did not alter the proliferative activity of splenocytes to concanavalin A; 200,000 U of rIL-2 per day actually depressed the proliferative responses of splenocytes from normal and infected mice. In vivo, rIL-2 did not modify delayed-type hypersensitivity responses to sheep erythrocytes or to histoplasmin by normal and infected mice. Moreover, treatment with rIL-2 in vivo did not reduce the number of Histoplasma CFU in spleens of mice. Thus, despite the immunoenhancing effect of rIL-2 in vitro, this lymphokine failed to exert similar effects in vivo.

Full text

PDF
6

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alcocer-Varela J., Alarcón-Segovia D. Decreased production of and response to interleukin-2 by cultured lymphocytes from patients with systemic lupus erythematosus. J Clin Invest. 1982 Jun;69(6):1388–1392. doi: 10.1172/JCI110579. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Artz R. P., Bullock W. E. Immunoregulatory responses in experimental disseminated histoplasmosis: depression of T-cell-dependent and T-effectory responses by activation of splenic suppressor cells. Infect Immun. 1979 Mar;23(3):893–902. doi: 10.1128/iai.23.3.893-902.1979. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Cheever M. A., Thompson J. A., Kern D. E., Greenberg P. D. Interleukin 2 (IL 2) administered in vivo: influence of IL 2 route and timing on T cell growth. J Immunol. 1985 Jun;134(6):3895–3900. [PubMed] [Google Scholar]
  4. Choromanski L., Kuhn R. E. Interleukin 2 enhances specific and nonspecific immune responses in experimental Chagas' disease. Infect Immun. 1985 Nov;50(2):354–357. doi: 10.1128/iai.50.2.354-357.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Cunningham A. J., Szenberg A. Further improvements in the plaque technique for detecting single antibody-forming cells. Immunology. 1968 Apr;14(4):599–600. [PMC free article] [PubMed] [Google Scholar]
  6. Deepe G. S., Jr, Watson S. R., Bullock W. E. Cellular origins and target cells of immunoregulatory factors in mice with disseminated histoplasmosis. J Immunol. 1984 Apr;132(4):2064–2071. [PubMed] [Google Scholar]
  7. Emmrich F., Moll H., Simon M. M. Recombinant human interleukin 2 acts as a B cell growth and differentiation promoting factor. Immunobiology. 1985 Feb;169(1):97–102. doi: 10.1016/S0171-2985(85)80057-7. [DOI] [PubMed] [Google Scholar]
  8. Farrar J. J., Benjamin W. R., Hilfiker M. L., Howard M., Farrar W. L., Fuller-Farrar J. The biochemistry, biology, and role of interleukin 2 in the induction of cytotoxic T cell and antibody-forming B cell responses. Immunol Rev. 1982;63:129–166. doi: 10.1111/j.1600-065x.1982.tb00414.x. [DOI] [PubMed] [Google Scholar]
  9. Hardt C., Röllinghoff M., Pfizenmaier K., Mosmann H., Wagner H. Lyt-23+ cyclophosphamide-sensitive T cells regulate the activity of an interleukin 2 inhibitor in vivo. J Exp Med. 1981 Aug 1;154(2):262–274. doi: 10.1084/jem.154.2.262. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Harel-Bellan A., Joskowicz M., Fradelizi D., Eisen H. Modification of T-cell proliferation and interleukin 2 production in mice infected with Trypanosoma cruzi. Proc Natl Acad Sci U S A. 1983 Jun;80(11):3466–3469. doi: 10.1073/pnas.80.11.3466. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Hünig T., Schimpl A., Wecker E. Autoradiographic studies on the proliferation of antibody-producing cells in vitro. J Exp Med. 1974 Mar 1;139(3):754–760. doi: 10.1084/jem.139.3.754. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Julius M. H., Simpson E., Herzenberg L. A. A rapid method for the isolation of functional thymus-derived murine lymphocytes. Eur J Immunol. 1973 Oct;3(10):645–649. doi: 10.1002/eji.1830031011. [DOI] [PubMed] [Google Scholar]
  13. Kurnick J. T., Grönvik K. O., Kimura A. K., Lindblom J. B., Skoog V. T., Sjöberg O., Wigzell H. Long term growth in vitro of human T cell blasts with maintenance of specificity and function. J Immunol. 1979 Apr;122(4):1255–1260. [PubMed] [Google Scholar]
  14. Lefrancois L., Klein J. R., Paetkau V., Bevan M. J. Antigen-independent activation of memory cytotoxic T cells by interleukin 2. J Immunol. 1984 Apr;132(4):1845–1850. [PubMed] [Google Scholar]
  15. Lotze M. T., Matory Y. L., Ettinghausen S. E., Rayner A. A., Sharrow S. O., Seipp C. A., Custer M. C., Rosenberg S. A. In vivo administration of purified human interleukin 2. II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2. J Immunol. 1985 Oct;135(4):2865–2875. [PubMed] [Google Scholar]
  16. Lowenthal J. W., Zubler R. H., Nabholz M., MacDonald H. R. Similarities between interleukin-2 receptor number and affinity on activated B and T lymphocytes. Nature. 1985 Jun 20;315(6021):669–672. doi: 10.1038/315669a0. [DOI] [PubMed] [Google Scholar]
  17. Mishell R. I., Dutton R. W. Immunization of dissociated spleen cell cultures from normal mice. J Exp Med. 1967 Sep 1;126(3):423–442. doi: 10.1084/jem.126.3.423. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Mohagheghpour N., Gelber R. H., Larrick J. W., Sasaki D. T., Brennan P. J., Engleman E. G. Defective cell-mediated immunity in leprosy: failure of T cells from lepromatous leprosy patients to respond to Mycobacterium leprae is associated with defective expression of interleukin 2 receptors and is not reconstituted by interleukin 2. J Immunol. 1985 Aug;135(2):1443–1449. [PubMed] [Google Scholar]
  19. Nickerson D. A., Havens R. A., Bullock W. E. Immunoregulation in disseminated histoplasmosis: characterization of splenic suppressor cell populations. Cell Immunol. 1981 May 15;60(2):287–297. doi: 10.1016/0008-8749(81)90270-7. [DOI] [PubMed] [Google Scholar]
  20. Pearlstein K. T., Palladino M. A., Welte K., Vilcek J. Purified human interleukin-2 enhances induction of immune interferon. Cell Immunol. 1983 Aug;80(1):1–9. doi: 10.1016/0008-8749(83)90088-6. [DOI] [PubMed] [Google Scholar]
  21. Reiner N. E., Finke J. H. Interleukin 2 deficiency in murine Leishmaniasis donovani and its relationship to depressed spleen cell responses to phytohemagglutinin. J Immunol. 1983 Sep;131(3):1487–1491. [PubMed] [Google Scholar]
  22. Rosenberg S. A., Grimm E. A., McGrogan M., Doyle M., Kawasaki E., Koths K., Mark D. F. Biological activity of recombinant human interleukin-2 produced in Escherichia coli. Science. 1984 Mar 30;223(4643):1412–1414. doi: 10.1126/science.6367046. [DOI] [PubMed] [Google Scholar]
  23. Schimpl A., Wecker E. Replacement of T-cell function by a T-cell product. Nat New Biol. 1972 May 3;237(70):15–17. doi: 10.1038/newbio237015a0. [DOI] [PubMed] [Google Scholar]
  24. Sharma S. D., Hofflin J. M., Remington J. S. In vivo recombinant interleukin 2 administration enhances survival against a lethal challenge with Toxoplasma gondii. J Immunol. 1985 Dec;135(6):4160–4163. [PubMed] [Google Scholar]
  25. Watson J., Mochizuki D. Interleukin 2: a class of T cell growth factors. Immunol Rev. 1980;51:257–278. doi: 10.1111/j.1600-065x.1980.tb00324.x. [DOI] [PubMed] [Google Scholar]
  26. Watson S. R., Schmitt S. K., Hendricks D. E., Bullock W. E. Immunoregulation in disseminated murine histoplasmosis: disturbances in the production of interleukins 1 and 2. J Immunol. 1985 Nov;135(5):3487–3493. [PubMed] [Google Scholar]
  27. Weigent D. A., Stanton G. J., Johnson H. M. Interleukin 2 enhances natural killer cell activity through induction of gamma interferon. Infect Immun. 1983 Sep;41(3):992–997. doi: 10.1128/iai.41.3.992-997.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Wofsy D., Murphy E. D., Roths J. B., Dauphinée M. J., Kipper S. B., Talal N. Deficient interleukin 2 activity in MRL/Mp and C57BL/6J mice bearing the lpr gene. J Exp Med. 1981 Nov 1;154(5):1671–1680. doi: 10.1084/jem.154.5.1671. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES